Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe CKD
Status:
Not yet recruiting
Trial end date:
2024-03-15
Target enrollment:
Participant gender:
Summary
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group,
multicenter study with randomized withdrawal will evaluate the efficacy, safety, and
durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD)
(estimated glomerular filtration rate [eGFR] ≥15 to ≤44 mL/min/1.73 m^2) and uncontrolled
hypertension (systolic blood pressure (SBP) ≥140 and <180 mm Hg and taking 2 or more
antihypertensive medications.